The Case for Proportionate Regulatory Scrutiny of Emerging Therapeutic Peptides
Regulating emerging therapies should not proceed without a proportional analysis of the effect on patient outcomes and risks.
Health Practitioners Ombudsman ‘Immeadiate Powers’ Review
My experience with AHPRA Investigators and the Board - the motivation behind much of my advocacy and educational work.
Revised National Prescribing Competencies Framework (3rd Edition)
Is AHPRA spending money it doesn’t have doing things that are unlikely to affect patient outcomes?